Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

NCT05087758 · View on ClinicalTrials.gov ↗

Study Summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.

Interventions

  • OTHER Matrion
  • OTHER Conventional Care Wound Management

Study Locations (8)

California

  • Center for Clinical Research, INC — Carmichael
  • Limb Preservation Platform, INC — Fresno
  • ILD Research Center — San Diego
  • Center for Clinical Research, INC — San Francisco

Arizona

  • Compass Medical Research Center, LLC — Tucson

Florida

  • Doctors Research Network — Miami

New Mexico

  • Albuquerque Associated Podiatrists — Albuquerque

North Carolina

  • Purvis-Moyer Foot and Ankle Center — Rocky Mount

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2022-03-01
Est. Completion 2025-02-28
Phase NA

Sponsor

LifeNet Health

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05087758

The ClinicalTrials.gov registry entry for NCT05087758 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LifeNet Health, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Diabetic Foot appearing as the primary indexed condition, and to 2 interventions — of which Matrion is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05087758 reports 8 study locations spanning 5 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05087758 about?

NCT05087758 is a clinical study titled "Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers". In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and...

What is the current status of trial NCT05087758?

This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2022-03-01. Estimated completion is 2025-02-28.

What conditions does trial NCT05087758 study?

This clinical trial studies the following conditions: Diabetic Foot, Lower Extremity Wound. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05087758?

The interventions under investigation include: Matrion (OTHER), Conventional Care Wound Management (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05087758?

This trial is sponsored by LifeNet Health, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05087758 being conducted?

This trial has 8 study locations across Arizona, California, Florida, New Mexico, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial